Vera Therapeutics (VERA) News Today $30.76 +0.77 (+2.57%) As of 11:31 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share News and Trends Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest Vera Therapeutics Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2026 September 2026 August 2026 July 2026 June 2026 May 2026 April 2026 March 2026 February 2026 January 2026 December 2025 November 2025 October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 Time Period More filters Fewer filters Done Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK) and Vera Therapeutics (VERA)October 27 at 3:22 AM | theglobeandmail.comWedbush Sticks to Their Hold Rating for Vera Therapeutics (VERA)October 24, 2026 | theglobeandmail.comVera Therapeutics' TRUTAKNA Delivers Strong Phase III IgA Nephropathy ResultsOctober 22, 2026 | marketbeat.comVera Therapeutics, Inc. (VERA) Discusses Final Efficacy Results of ORIGIN Phase III Trial of Atacicept in IgA Nephropathy TranscriptOctober 22, 2026 | seekingalpha.comVera's TRUTAKNA Shows Kidney Benefit In Final Phase 3 IgA Nephropathy AnalysisOctober 22, 2026 | rttnews.comVera Therapeutics Announces Positive ORIGIN 3 Final Efficacy Analysis of TRUTAKNA™ (atacicept-vymj) in IgA Nephropathy Presented at ASN Kidney Week 2026 and Published in the ...October 22, 2026 | markets.businessinsider.comVera Therapeutics Announces ORIGIN 3 Final Analysis Shows TRUTAKNA Met All Prespecified Endpoints in IgA NephropathyOctober 22, 2026 | quiverquant.comQVera Therapeutics Announces Positive ORIGIN 3 Final Efficacy Analysis of TRUTAKNA™ (atacicept-vymj) in IgA Nephropathy Presented at ASN Kidney Week 2026 and Published in the New England Journal of MedicineOctober 22, 2026 | globenewswire.comVera Therapeutics to Host ASN Kidney Week Investor Webcast and Third Quarter 2026 Financial Results Conference WebcastOctober 20, 2026 | globenewswire.comGermany’s Merck to buy UK biotech Silence Therapeutics for $1.3 billionOctober 19, 2026 | msn.comCan Vera Therapeutics Stage Another Comeback?October 14, 2026 | rttnews.comLeerink Partners initiates coverage of Vera Therapeutics at market performOctober 13, 2026 | msn.comLeerink Partners Initiates Vera Therapeutics at Market Perform With $34 Price TargetOctober 13, 2026 | finance.yahoo.comLeerink Partners Begins Coverage on Vera Therapeutics (NASDAQ:VERA)October 12, 2026 | marketbeat.comBofA Securities Adjusts Vera Therapeutics Price Target to $60 From $66, Maintains Buy RatingOctober 9, 2026 | finance.yahoo.comVera Therapeutics, Inc. (NASDAQ:VERA) Stock Has Consensus Price Target of $80.15October 8, 2026 | marketbeat.comVera Therapeutics Announces ORIGIN 3 Final Efficacy Analysis of TRUTAKNA in IgA Nephropathy Will be A Featured Late-breaking Oral Presentation at the Opening Plenary Session of ...October 5, 2026 | marketscreener.comMVera Therapeutics Announces Origin 3 Final Efficacy Analysis of TRUTAKNA in Iga Nephropathy Will Be A Featured Late-Breaking Oral Presentation At Asn Kidney Week 2026October 3, 2026 | marketscreener.comMVera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)October 2, 2026 | globenewswire.comVera Therapeutics Announces ORIGIN 3 Final Efficacy Analysis of TRUTAKNA™ (atacicept-vymj) in IgA Nephropathy Will be A Featured Late-breaking Oral Presentation at the ...October 2, 2026 | finance.yahoo.comVera Therapeutics Announces ORIGIN 3 Final Efficacy Analysis of TRUTAKNA™ (atacicept-vymj) in IgA Nephropathy Will be A Featured Late-breaking Oral Presentation at the Opening Plenary Session of ASN Kidney Week 2026October 2, 2026 | globenewswire.comInsider Selling: Vera Therapeutics (NASDAQ:VERA) CEO Sells 18,500 Shares of StockSeptember 18, 2026 | insidertrades.comAnalysts Offer Insights on Healthcare Companies: Viatris (VTRS) and Vera Therapeutics (VERA)September 17, 2026 | theglobeandmail.comVera Therapeutics (VERA) Says TRUTAKNA Met All Phase III EndpointsSeptember 17, 2026 | finance.yahoo.comVera Therapeutics, Inc. (VERA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeptember 15, 2026 | seekingalpha.comVera set up for full approval for Trutakna in IgAN with Phase III winSeptember 15, 2026 | msn.comVera Therapeutics Shares Rise 13% After TRUTAKNA Meets ORIGIN 3 Trial EndpointsSeptember 15, 2026 | finance.yahoo.comVera Therapeutics: Why I'm Sticking With 'Hold' Despite Today's Positive Trutakna DataSeptember 15, 2026 | seekingalpha.comVera Therapeutics Shares Gain on Positive Late-Stage Trial ResultsSeptember 15, 2026 | marketwatch.comWhat's Going on With Vera Therapeutics Stock on Tuesday?September 15, 2026 | benzinga.comWhy Vera Therapeutics Stock Is Jumping on New Kidney Drug Trial ResultsSeptember 15, 2026 | barrons.comVera's TRUTAKNA Shows Two-Year Kidney Protection; SBLA Planned Q4 2026; Stock UpSeptember 15, 2026 | rttnews.comVera's TRUTAKNA Shows Two-Year Kidney Protection; SBLA Planned Q4 2026; Stock UpSeptember 15, 2026 | rttnews.comVera set for full FDA approval of Trutakna after late-stage trial winSeptember 15, 2026 | seekingalpha.comVera Therapeutics Announces TRUTAKNA™ (atacicept-vymj) Stabilized eGFR and Prevented Kidney Disease Progression Through Two Years in ORIGIN 3 Final Efficacy Analysis in IgA ...September 15, 2026 | markets.businessinsider.comVera Therapeutics Kidney Disease Drug Meets Prespecified Endpoints in Origin 3 TrialSeptember 15, 2026 | finance.yahoo.comVera Therapeutics Announces TRUTAKNA Met All Endpoints in ORIGIN 3 Final Analysis in IgA Nephropathy, with Strong Launch Momentum and Plans for FDA Supplemental BLA SubmissionSeptember 15, 2026 | quiverquant.comQVera Therapeutics Announces TRUTAKNA™ (atacicept-vymj) Stabilized eGFR and Prevented Kidney Disease Progression Through Two Years in ORIGIN 3 Final Efficacy Analysis in IgA NephropathySeptember 15, 2026 | globenewswire.comVera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)September 4, 2026 | globenewswire.comVera Therapeutics to Participate at Upcoming Investor ConferencesSeptember 1, 2026 | globenewswire.comVera Therapeutics, Inc. (VERA) Stock Price, News, Quote & History - Yahoo FinanceAugust 25, 2026 | finance.yahoo.comJ.P. Morgan Sticks to Their Buy Rating for Vera Therapeutics (VERA)August 19, 2026 | theglobeandmail.comVera Therapeutics: FDA's eGFR Analysis Supports A Speculative BuyAugust 17, 2026 | seekingalpha.comAnalysts Offer Insights on Healthcare Companies: Clinigence Holdings (NUTX), Vera Therapeutics (VERA) and Solid Biosciences (SLDB)August 12, 2026 | theglobeandmail.comVera Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial ResultsAugust 10, 2026 | markets.businessinsider.comSilence Therapeutics shares surge ahead of divesiran Phase 2 results callAugust 10, 2026 | finance.yahoo.comVera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)August 7, 2026 | globenewswire.comVera Therapeutics Inc - Ordinary Shares - Class AJuly 13, 2026 | money.usnews.comAnalysts Offer Insights on Healthcare Companies: Vera Therapeutics (VERA), Crinetics Pharmaceuticals (CRNX) and Revolution Medicines (RVMD)July 12, 2026 | theglobeandmail.comVera Therapeutics (VERA) Stock Looks Fully Valued After Its 185% RunJuly 10, 2026 | finance.yahoo.com Vera Therapeutics Media Mentions By Week Vera Therapeutics Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VERA News Sentiment▼0.620.69▲Average Healthcare News Sentiment Vera Therapeutics News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VERA Articles This Week▼95▲VERA Articles Average Week Vera Therapeutics Trends on MarketBeatThis week vs. last weekNew Followers1Searches1-50%Page Views2,948-7% Get Vera Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VERA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Arrowhead Pharmaceuticals News Today Abivax News Today Cytokinetics News Today Ionis Pharmaceuticals News Today Alkermes News Today Praxis Precision Medicines News Today Iovance Biotherapeutics News Today Kiniksa Pharmaceuticals International News Today Rhythm Pharmaceuticals News Today Ligand Pharmaceuticals News Today News and Trends Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas MarketBeat tracks news from more than one hundred trusted media outlets in real time, with the most recent headline for Vera Therapeutics dated 10/27/2026. From Our PartnersFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredElon Musk’s One Stock Retirement PlanStanley Druckenmiller once said you don't get rich diversifying into 50 mediocre assets - you get rich finding...Brownstone Research | Sponsored80 Days Until America's Rare Earth Supply Chain ShiftChina controls more than 90% of global rare earth alloy production, leverage it is using to restrict exports t...The Tomorrow Investor | SponsoredMy next big call (under $1)17,556% on KDA. 3,900% on PRE. 2,650% on OCEAN. Every single one of these was recommended to our community bef...Crypto 101 Media | SponsoredBezos… DOOMED?A single FCC filing hints Elon Musk is planning his biggest project yet - bigger than Tesla, SpaceX, and X com...Paradigm Press | SponsoredAnd they say the headline number understates what’s really happening.Goldman Sachs just admitted it underestimated central bank gold purchases by more than 500 percent, with buyin...Cedar Gold Group | SponsoredExecutive Order 14241 Unleashes Trump’s New DollarA landmark executive order, 14241, is reportedly set to reshape how Americans use money starting this December...Porter & Company | SponsoredYour book is insideBlane Markham and the Markham Trading Team are giving readers a limited window to download their options strat...TradeWins | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vera Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vera Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
